Biosimilar Rituximab

About Cipla

Founded in 1935, Cipla has established itself as a pioneering pharmaceutical company committed to improving global health outcomes through affordable medicines. The company operates across multiple therapeutic areas including respiratory, oncology, anti-retroviral, and complex generics, with a particular strength in inhalation products and biosimilars. Cipla's integrated business model spans from API manufacturing to finished formulations, with a growing focus on digital health solutions and specialty products for developed markets.

About Ipca Laboratories

Ipca Laboratories Ltd. is a prominent, fully integrated Indian pharmaceutical company with a significant global footprint in over 120 countries. Its core strengths lie in its vertical integration, from API manufacturing to finished formulations, particularly in therapeutic segments like anti-malarials, NSAIDs, and anti-diabetics. The company has a diversified business model spanning domestic formulations, international branded generics, and API exports, and is strategically focused on expanding its presence in regulated markets like the US while navigating complex regulatory landscapes.

Therapeutic Areas